Healthy AgeingREGEN-CNCT07521423
Effects of a Dietary Supplement on Collagen Production and Evaluation of Its Regenerative and Anti-Ageing Propertiess
A study testing Collagen-Supporting Nutraceutical Formulation in people with Healthy Ageing and Skin Ageing, run by Marianna Kapetanou at 1 site in Greece.
Trial summary
This study evaluates the effects of a dietary supplement containing natural bioactive compounds on biological processes associated with skin ageing and extracellular matrix integrity. Read more about this study
- Who is it for?
- Ages 29 to 82 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Ageing, Skin Ageing, Oxidative Stress
- What is being tested?
- Collagen-Supporting Nutraceutical Formulation
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 92 participants
- Where
- 1 siteGreece
- Study dates
- 1 Oct 2025to 1 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 29 to 82 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged 29 to 82 years Individuals with Fitzpatrick skin types I-VI Presence of mild to moderate fine lines and wrinkles Presence of mild to moderate photoaging consistent with chronological ageing Generally healthy individuals without known medical conditions that, in the opinion of the investigator, could interfere with study participation Ability to understand the study procedures and provide written informed consent
Who cannot join
- 1. Body mass index (BMI) greater than 28 kg/m² Current diagnosis of cancer and/or undergoing chemotherapy or radiotherapy Use of dietary supplements during the study period Ongoing long-term treatment for autoimmune or chronic diseases Pregnancy, breastfeeding, or intention to become pregnant during the study period Severe photoaging beyond mild to moderate classification History of cosmetic procedures or dermatological conditions that, in the opinion of the investigator, could interfere with accurate skin assessment, including but not limited to rosacea, acne, or excessively oily or dry skin Known hypersensitivity or allergic reaction to any component of the study product
Trial locations and contacts
1 site in 1 country.
About this study
This study evaluates the effects of a dietary supplement containing natural bioactive compounds on biological processes associated with skin ageing and extracellular matrix integrity. Ageing is characterized by a progressive decline in the function of dermal fibroblasts, the primary cells responsible for collagen production and maintenance of skin structure. Over time, these cells exhibit reduced proliferative capacity, decreased collagen synthesis, and increased accumulation of oxidative and glycative damage, leading to deterioration of skin elasticity and overall tissue homeostasis.
The study integrates in vitro and clinical approaches to investigate the potential benefits of the formulation. In the clinical component, healthy adult participants received either the nutraceutical formulation or a matched placebo daily for a period of six weeks. Blood samples were collected at baseline and at the end of the intervention to assess changes in systemic biomarkers associated with collagen metabolism, oxidative stress, and glycation.
Read more
Specifically, the study measured circulating levels of Pro-Collagen I Alpha as an indicator of collagen biosynthesis, protein carbonyls as markers of oxidative protein damage, and Advanced Glycation End Products as markers of glycation-related molecular damage. These biomarkers collectively reflect key biological mechanisms underlying skin ageing and broader ageing processes.
The objective of the study is to determine whether supplementation with the formulation can support extracellular matrix homeostasis, enhance collagen production, and reduce molecular damage associated with oxidative stress and glycation, thereby contributing to healthy ageing.
Read the detailed description
Ageing of the skin is a multifactorial biological process characterized by progressive structural and functional decline of the dermis. Dermal fibroblasts are the principal cells responsible for the synthesis and maintenance of the extracellular matrix (ECM), including type I and type III collagen, which are essential for maintaining skin integrity, elasticity, and mechanical strength. During ageing, fibroblasts progressively lose proliferative capacity and enter a state of replicative senescence associated with irreversible cell-cycle arrest and altered cellular function. This transition is driven by mechanisms such as telomere shortening, oxidative stress, mitochondrial dysfunction, and persistent DNA damage responses, ultimately leading to reduced collagen synthesis and impaired tissue repair.
In parallel, ageing is accompanied by increased oxidative and glycative stress, which contribute to cumulative molecular damage. Oxidative modification of proteins results in the formation of protein carbonyls, widely recognized as stable markers of oxidative protein damage. Glycation reactions lead to the formation of Advanced Glycation End Products (AGEs), which accumulate in long-lived proteins such as collagen, promoting crosslinking, reduced tissue elasticity, and impaired extracellular matrix remodeling. These processes are further amplified by the accumulation of senescent fibroblasts, which secrete pro-inflammatory and matrix-remodeling factors, contributing to chronic low-grade inflammation and progressive tissue deterioration.
Targeting these interconnected mechanisms, including extracellular matrix metabolism, oxidative stress, glycation, and proteostasis, represents a promising strategy for supporting healthy ageing. Nutraceutical formulations containing natural bioactive compounds have emerged as potential modulators of these pathways, with evidence suggesting their ability to enhance antioxidant defenses, reduce protein damage, and support collagen biosynthesis.
The present study applies a translational framework to evaluate the biological effects of a collagen-supporting nutraceutical formulation. The investigation included an initial in vitro component using human fibroblasts to assess cellular responses related to ageing dynamics, followed by a randomized, placebo-controlled clinical intervention in healthy adults to determine systemic effects.
In the clinical study, participants received either the nutraceutical formulation or a matched placebo administered orally for six consecutive weeks. The formulation consisted of a combination of structural components of collagen, amino acids involved in collagen biosynthesis, antioxidants, enzymatic cofactors, and micronutrients supporting skin and cellular homeostasis. Specifically, each tablet contained hydrolyzed marine collagen peptides (200 mg) and hyaluronic acid (100 mg) to support extracellular matrix structure and hydration. It also included key amino acids required for collagen synthesis, namely glycine (120 mg), proline (60 mg), and hydroxyproline (60 mg), which contribute to collagen formation, stabilization, and maturation.
To address oxidative stress and molecular damage, the formulation incorporated antioxidant compounds including quercetin (50 mg), reduced glutathione (50 mg), and astaxanthin (0.1 mg), aiming to enhance cellular redox balance and protect proteins and membranes from oxidative modification. In addition, vitamin C (80 mg) and zinc (10 mg) were included as essential cofactors for enzymatic processes involved in collagen biosynthesis. The formulation was further supplemented with vitamin D3 (30 μg, 1200 IU) and biotin (100 μg) to support cellular homeostasis, skin health, and metabolic regulation. Excipients were included to ensure stability and appropriate tablet formulation.
Blood samples were collected at baseline and at the end of the intervention period to evaluate changes in circulating biomarkers associated with key biological processes relevant to ageing. The selected biomarkers included Pro-Collagen I Alpha as an indicator of collagen biosynthesis and extracellular matrix turnover, protein carbonyls as markers of oxidative protein damage, and Advanced Glycation End Products as markers of glycation burden. Together, these biomarkers provide complementary information on collagen metabolism, oxidative stress, and protein modification, allowing for an integrated assessment of biological ageing processes.
The study is designed to determine whether supplementation with the formulation can modulate these biomarkers in a manner consistent with improved extracellular matrix homeostasis and reduced molecular damage. By focusing on measurable systemic endpoints linked to fundamental mechanisms of ageing, the study aims to provide evidence for the potential role of targeted nutraceutical interventions in supporting skin health and broader healthy ageing trajectories.
- Conditions
- Healthy Ageing, Skin Ageing, Oxidative Stress
- Being tested
- Collagen-Supporting Nutraceutical Formulation, Placebo
- Keywords
- Healthy Ageing, Skin Ageing, Collagen Biosynthesis, Extracellular Matrix, Oxidative Stress, Protein Carbonyls, Advanced Glycation End Products, Proteostasis, Nutraceutical, Dietary Supplement, Antioxidants, Collagen Metabolism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Collagen-Supporting Nutraceutical FormulationDietary supplement
The intervention consists of an oral dietary supplement formulated to support collagen biosynthesis and extracellular matrix homeostasis. Each tablet contains hydrolyzed marine collagen peptides, hyaluronic acid, and amino acids (glycine, proline, hydroxyproline) involved in collagen formation and stabilization. The formulation also includes antioxidant compounds (quercetin, reduced glutathione, astaxanthin) to support redox balance, as well as vitamin C and zinc as cofactors in collagen synthesis. Additional components include vitamin D3 and biotin to support cellular and skin health. The supplement is administered daily for six weeks.
PlaceboDietary supplement
The placebo consists of an inert oral formulation matched in appearance and administration schedule to the active dietary supplement. It contains excipients without active bioactive ingredients and is administered daily for six weeks.
| Study group | Role | What they receive |
|---|---|---|
| Nutraceutical Formulation | Experimental | Participants receive an oral nutraceutical formulation containing collagen peptides, amino acids, antioxidants, vitamins, and trace elements designed to support collagen biosynthesis, extracellular matrix homeostasis, and reduction of oxidative and glycative stress. The formulation is administered daily for six weeks. Receives: Dietary Supplement: Collagen-Supporting Nutraceutical Formulation |
| Placebo Comparator | Placebo comparator | Participants receive a matched placebo formulation administered orally on a daily basis for six weeks. The placebo is similar in appearance and dosing schedule to the active intervention but does not contain bioactive ingredients. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in plasma Pro-Collagen I Alpha levels
Change in circulating Pro-Collagen I Alpha concentrations as a biomarker of collagen biosynthesis and extracellular matrix turnover.
Measured: Baseline (Day 0) and Week 6
Change in plasma protein carbonyl levels
Change in plasma protein carbonyl concentrations as a measure of oxidative protein damage.
Measured: Baseline (Day 0) and Week 6
Change in plasma Advanced Glycation End Products (AGEs) levels
Change in plasma AGEs concentrations as a measure of glycation-related molecular damage.
Measured: Baseline (Day 0) and Week 6
Secondary outcomes (1)
Participant-reported self-assessment of skin-related effects and tolerability
Self-administered participant questionnaire evaluating perceived effects of the intervention on skin appearance and condition, including elasticity, hydration, wrinkle appearance, pigmentation-related changes, and overall skin quality, together with general well-being and any self-reported adverse effects.
Measured: Week 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Apr 2026
- Study start1 Oct 2025
- Primary completion1 Feb 2026
- Study completion1 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy AgeingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 92 participants (actual)
Sponsor and investigators
- Lead sponsor
- Marianna Kapetanou
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Marianna Kapetanou, Hellenic Pasteur Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07521423
- Sponsor's protocol ID
- 3 8 1 3 / 1 7 - 0 6 - 2 0 2 4
- Acronym
- REGEN-C
- Status last verified
- Mar 2026
- First submitted
- 3 Apr 2026
- Last updated
- 9 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual Participant Data (IPD) will not be shared due to privacy and data protection considerations, including compliance with applicable regulations such as the General Data Protection Regulation (GDPR). Data will be reported and made available in aggregate form to ensure participant confidentiality.
Study at a glance
From the registry record, last updated by the sponsor on 9 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of a Dietary Supplement on Collagen Production and Evaluation of Its Regenerative and Anti-Ageing Propertiess
- ClinicalTrials.gov ID
- NCT07521423
- Acronym / sponsor ID
- REGEN-C / 3 8 1 3 / 1 7 - 0 6 - 2 0 2 4
- Conditions
- Healthy Ageing, Skin Ageing, Oxidative Stress
- Keywords
- Healthy Ageing, Skin Ageing, Collagen Biosynthesis, Extracellular Matrix, Oxidative Stress, Protein Carbonyls, Advanced Glycation End Products, Proteostasis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 92 participants (actual)
- Lead sponsor
- Marianna KapetanouUniversity, hospital or other
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- 1 Feb 2026 (actual)
- Study completion
- 1 Mar 2026 (actual)
- First posted
- 9 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the effects of a dietary supplement containing natural bioactive compounds on biological processes associated with skin ageing and extracellular matrix integrity. Ageing is characterized by a progressive decline in the function of dermal fibroblasts, the primary cells responsible for collagen production and maintenance of skin structure. Over time, these cells exhibit reduced proliferative capacity, decreased collagen synthesis, and increased accumulation of oxidative and glycative damage, leading to deterioration of skin elasticity and overall tissue homeostasis.
The study integrates in vitro and clinical approaches to investigate the potential benefits of the formulation. In the clinical component, healthy adult participants received either the nutraceutical formulation or a matched placebo daily for a period of six weeks. Blood samples were collected at baseline and at the end of the intervention to assess changes in systemic biomarkers associated with collagen metabolism, oxidative stress, and glycation.
Specifically, the study measured circulating levels of Pro-Collagen I Alpha as an indicator of collagen biosynthesis, protein carbonyls as markers of oxidative protein damage, and Advanced Glycation End Products as markers of glycation-related molecular damage. These biomarkers collectively reflect key biological mechanisms underlying skin ageing and broader ageing processes.
The objective of the study is to determine whether supplementation with the formulation can support extracellular matrix homeostasis, enhance collagen production, and reduce molecular damage associated with oxidative stress and glycation, thereby contributing to healthy ageing.
Detailed description
Ageing of the skin is a multifactorial biological process characterized by progressive structural and functional decline of the dermis. Dermal fibroblasts are the principal cells responsible for the synthesis and maintenance of the extracellular matrix (ECM), including type I and type III collagen, which are essential for maintaining skin integrity, elasticity, and mechanical strength. During ageing, fibroblasts progressively lose proliferative capacity and enter a state of replicative senescence associated with irreversible cell-cycle arrest and altered cellular function. This transition is driven by mechanisms such as telomere shortening, oxidative stress, mitochondrial dysfunction, and persistent DNA damage responses, ultimately leading to reduced collagen synthesis and impaired tissue repair.
In parallel, ageing is accompanied by increased oxidative and glycative stress, which contribute to cumulative molecular damage. Oxidative modification of proteins results in the formation of protein carbonyls, widely recognized as stable markers of oxidative protein damage. Glycation reactions lead to the formation of Advanced Glycation End Products (AGEs), which accumulate in long-lived proteins such as collagen, promoting crosslinking, reduced tissue elasticity, and impaired extracellular matrix remodeling. These processes are further amplified by the accumulation of senescent fibroblasts, which secrete pro-inflammatory and matrix-remodeling factors, contributing to chronic low-grade inflammation and progressive tissue deterioration.
Targeting these interconnected mechanisms, including extracellular matrix metabolism, oxidative stress, glycation, and proteostasis, represents a promising strategy for supporting healthy ageing. Nutraceutical formulations containing natural bioactive compounds have emerged as potential modulators of these pathways, with evidence suggesting their ability to enhance antioxidant defenses, reduce protein damage, and support collagen biosynthesis.
The present study applies a translational framework to evaluate the biological effects of a collagen-supporting nutraceutical formulation. The investigation included an initial in vitro component using human fibroblasts to assess cellular responses related to ageing dynamics, followed by a randomized, placebo-controlled clinical intervention in healthy adults to determine systemic effects.
In the clinical study, participants received either the nutraceutical formulation or a matched placebo administered orally for six consecutive weeks. The formulation consisted of a combination of structural components of collagen, amino acids involved in collagen biosynthesis, antioxidants, enzymatic cofactors, and micronutrients supporting skin and cellular homeostasis. Specifically, each tablet contained hydrolyzed marine collagen peptides (200 mg) and hyaluronic acid (100 mg) to support extracellular matrix structure and hydration. It also included key amino acids required for collagen synthesis, namely glycine (120 mg), proline (60 mg), and hydroxyproline (60 mg), which contribute to collagen formation, stabilization, and maturation.
To address oxidative stress and molecular damage, the formulation incorporated antioxidant compounds including quercetin (50 mg), reduced glutathione (50 mg), and astaxanthin (0.1 mg), aiming to enhance cellular redox balance and protect proteins and membranes from oxidative modification. In addition, vitamin C (80 mg) and zinc (10 mg) were included as essential cofactors for enzymatic processes involved in collagen biosynthesis. The formulation was further supplemented with vitamin D3 (30 μg, 1200 IU) and biotin (100 μg) to support cellular homeostasis, skin health, and metabolic regulation. Excipients were included to ensure stability and appropriate tablet formulation.
Blood samples were collected at baseline and at the end of the intervention period to evaluate changes in circulating biomarkers associated with key biological processes relevant to ageing. The selected biomarkers included Pro-Collagen I Alpha as an indicator of collagen biosynthesis and extracellular matrix turnover, protein carbonyls as markers of oxidative protein damage, and Advanced Glycation End Products as markers of glycation burden. Together, these biomarkers provide complementary information on collagen metabolism, oxidative stress, and protein modification, allowing for an integrated assessment of biological ageing processes.
The study is designed to determine whether supplementation with the formulation can modulate these biomarkers in a manner consistent with improved extracellular matrix homeostasis and reduced molecular damage. By focusing on measurable systemic endpoints linked to fundamental mechanisms of ageing, the study aims to provide evidence for the potential role of targeted nutraceutical interventions in supporting skin health and broader healthy ageing trajectories.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Nutraceutical Formulation | Experimental | Dietary Supplement: Collagen-Supporting Nutraceutical FormulationParticipants receive an oral nutraceutical formulation containing collagen peptides, amino acids, antioxidants, vitamins, and trace elements designed to support collagen biosynthesis, extracellular matrix homeostasis, and reduction of oxidative and glycative stress. The formulation is administered daily for six weeks. |
| Placebo Comparator | Placebo comparator | Dietary Supplement: PlaceboParticipants receive a matched placebo formulation administered orally on a daily basis for six weeks. The placebo is similar in appearance and dosing schedule to the active intervention but does not contain bioactive ingredients. |
Who may qualify
- Ages
- 29 to 82 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Adults aged 29 to 82 years Individuals with Fitzpatrick skin types I-VI Presence of mild to moderate fine lines and wrinkles Presence of mild to moderate photoaging consistent with chronological ageing Generally healthy individuals without known medical conditions that, in the opinion of the investigator, could interfere with study participation Ability to understand the study procedures and provide written informed consent
Key exclusion criteria (1 listed)
- 1. Body mass index (BMI) greater than 28 kg/m² Current diagnosis of cancer and/or undergoing chemotherapy or radiotherapy Use of dietary supplements during the study period Ongoing long-term treatment for autoimmune or chronic diseases Pregnancy, breastfeeding, or intention to become pregnant during the study period Severe photoaging beyond mild to moderate classification History of cosmetic procedures or dermatological conditions that, in the opinion of the investigator, could interfere with accurate skin assessment, including but not limited to rosacea, acne, or excessively oily or dry skin Known hypersensitivity or allergic reaction to any component of the study product
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Collagen-Supporting Nutraceutical FormulationThe intervention consists of an oral dietary supplement formulated to support collagen biosynthesis and extracellular matrix homeostasis. Each tablet contains hydrolyzed marine collagen peptides, hyaluronic acid, and amino acids (glycine, proline, hydroxyproline) involved in collagen formation and stabilization. The formulation also includes antioxidant compounds (quercetin, reduced glutathione, astaxanthin) to support redox balance, as well as vitamin C and zinc as cofactors in collagen synthesis. Additional components include vitamin D3 and biotin to support cellular and skin health. The supplement is administered daily for six weeks. | Dietary supplement | Nutraceutical Formulation |
| PlaceboThe placebo consists of an inert oral formulation matched in appearance and administration schedule to the active dietary supplement. It contains excipients without active bioactive ingredients and is administered daily for six weeks. | Dietary supplement | Placebo Comparator |
Primary outcome
Change in plasma Pro-Collagen I Alpha levels
Time frame: Baseline (Day 0) and Week 6
Change in circulating Pro-Collagen I Alpha concentrations as a biomarker of collagen biosynthesis and extracellular matrix turnover.
Change in plasma protein carbonyl levels
Time frame: Baseline (Day 0) and Week 6
Change in plasma protein carbonyl concentrations as a measure of oxidative protein damage.
Change in plasma Advanced Glycation End Products (AGEs) levels
Time frame: Baseline (Day 0) and Week 6
Change in plasma AGEs concentrations as a measure of glycation-related molecular damage.
1 secondary outcome
Participant-reported self-assessment of skin-related effects and tolerability
Time frame: Week 6
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Apr 2026.
- Individual participant dataSharing planned: No. Individual Participant Data (IPD) will not be shared due to privacy and data protection considerations, including compliance with applicable regulations such as the General Data Protection Regulation (GDPR). Data will be reported and made available in aggregate form to ensure participant confidentiality.
Related trials for Healthy Ageing
Active, not recruiting
Effects of a Multi-Targeted Oral Supplement on Skin, Hair, Sleep, Energy, Cognition, Libido and Epigenetic Biological Clock Age
Skin Ageing, Healthy Ageing
Active, not recruiting
The Effects of PeptiStrong and Whey on Muscle Function In Older Adults
Healthy Ageing, Protein Supplementation
Enrolling by invitationObservational study
Intrinsic Capacity, Resilience, and Meaning in Life in Community-Dwelling Midlife and Older Adults
Healthy Ageing, Community-dwelling Older Adults
Recruiting
The ALIVE-Project: Activity, Life Satisfaction, Inclusion, Vitality, Elderly Women
Loneliness, Social Isolation in Older Adults
Not yet recruiting
Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence
Aging, Inflammation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Collagen-Supporting Nutraceutical Formulation in people with Healthy Ageing and Skin Ageing, run by Marianna Kapetanou at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in plasma Pro-Collagen I Alpha levels (time frame: Baseline (Day 0) and Week 6). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2026; AzTrials last refreshed its copy on 8 Nov 2026.